Fig. 1.

(A) SARS-CoV-2 IgG Spike titre (median with interquartile range (IQR)) in MS subjects treated with different DMTs, 21 days (T3) after the third dose compared to healthy controls (HC). Mann U- Whitney two-tailed test vs HC subjects was performed and a p-value less than 0.05 was considered statistically significant. * p<0.05; ***p<0.001. (B) SARS-CoV-2 IgG Spike titre kinetic (mean ± SEM) of MS subjects treated with different DMTs at 21 days (T1), ∼6 months (T2) after the second vaccine dose and 21 days (T3) after the third dose compared to HC. Wilcoxon two-tailed test was performed to compare T1, T2 and T3 levels and a p-value less than 0.05 was considered statistically significant. *^,§,#p<0.05; **^,§§,##p<0.01; ***^,§§§,###p<0.005. *T1 vs T2; ^§T1 vs T3; ^#T2 vs T3. (C) Geometric Mean Titre Ratio (GMTR) was obtained as the ratio between SARS-CoV-2 IgG Titre at 21 days after the third dose (T3) and at ∼6 months after the second (T2) dose of vaccine and between SARS-CoV-2 IgG Titre at 21 days after the third dose (T3) and 21 days after the second dose (T1) of vaccine. Data are reported as median with IQR. Mann U-Whitney two-tailed test vs HC and Wilcoxon two-tailed test were performed and a p-value less than 0.05 was considered statistically significant. *^,§,#p<0.05; ***p<0.005;

*T3/T2 GMTR vs T3/T1 GMTR of pwMS; ^§ T3/T2 GMTR of pwMS vs T3/T2 GMTR of HC; ^# T3/T1 GMTR of pwMS vs T3/T1 GMTR of HC.